ADC Therapeutics SA 13,411,912 Common SHares, nominal Value CHF 0.08 PER SHARE Pre-funded warrants to purchase 8,163,265 common sHARES, nominal Value CHF 0.08 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • May 8th, 2024 • ADC Therapeutics SA • Pharmaceutical preparations • New York
Contract Type FiledMay 8th, 2024 Company Industry JurisdictionJefferies LLC Guggenheim Securities, LLC Cantor Fitzgerald & Co. As Representatives of the several Underwriters named in Schedule I hereto
●] Shares ADC THERAPEUTICS SA COMMON SHARES, NOMINAL VALUE CHF 0.08 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • May 11th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York
Contract Type FiledMay 11th, 2020 Company Industry JurisdictionThis letter is being delivered to you in connection with the offering by ADC Therapeutics SA (the “Company”) of _____ common shares, nominal value CHF [●] per share (the “Common Shares”), of the Company and the lock-up letter dated ____, 2020 (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 2020, with respect to ____ Common Shares (the “Shares”).
●] Shares ADC THERAPEUTICS SA COMMON SHARES, NOMINAL VALUE CHF 0.064 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • September 23rd, 2019 • ADC Therapeutics SA • Pharmaceutical preparations • New York
Contract Type FiledSeptember 23rd, 2019 Company Industry JurisdictionThis letter is being delivered to you in connection with the offering by ADC Therapeutics SA (the “Company”) of _____ common shares, nominal value CHF [●] per share (the “Common Shares”), of the Company and the lock-up letter dated ____, 2019 (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 2019, with respect to ____ Common Shares (the “Shares”).